Clinical Trial Update: Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on tislelizumab plus anlotinib for immunotherapy-resistant gastric and colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking University | Conditions: Gastric Cancer, Colo-rectal Cancer | Phase 2 | Status: UNKNOWN